Sierra Oncology (SRRA) Short Interest Ratio & Short Volume

Short interest is the volume of Sierra Oncology shares that have been sold short but have not yet been closed out or covered. As of June 15th, investors have sold 571,500 shares of SRRA short. Learn More on Sierra Oncology's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SRRA shares currently have a short interest ratio of 1.0. Learn More on Sierra Oncology's short interest ratio.

Sierra Oncology saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 571,500 shares, a decline of 28.4% from the previous total of 797,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to Sierra Oncology: TG Therapeutics, Inc. (16.90%), Ionis Pharmaceuticals, Inc. (9.45%), Grifols, S.A. (1.26%), Axsome Therapeutics, Inc. (11.10%), Nuvalent, Inc. (13.62%), Alkermes plc (8.25%), Prestige Consumer Healthcare Inc. (3.23%), Cytokinetics, Incorporated (12.45%), Perrigo Company plc (3.85%), Rhythm Pharmaceuticals, Inc. (8.81%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.58 billion), Occidental Petroleum Co. ($3.23 billion), Lucid Group, Inc. ($2.31 billion), Coinbase Global, Inc. ($1.73 billion), Snowflake Inc. ($1.71 billion), Chesapeake Energy Co. ($1.66 billion), Rivian Automotive, Inc. ($1.63 billion), Williams-Sonoma, Inc. ($1.51 billion), Lumen Technologies, Inc. ($1.40 billion), and Diamondback Energy, Inc. ($1.37 billion). View all of the most shorted stocks.

Short selling SRRA is an investing strategy that aims to generate trading profit from Sierra Oncology as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Sierra Oncology occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SRRA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SRRA, twice per month. The most recent reporting period available is June, 15 2022.